Why Is KARDIGAN INC (KARD) Stock Down Today?

Kardigan (KARD) shares fell 5.38% to $13.36 following the release of third quarter 2026 financial results. The primary driver of the decline appears to be a price target reduction by Leerink, which lowered its outlook for the stock.

What Happened

Kardigan reported third quarter 2026 GAAP earnings per share of negative $0.64, a result that beat consensus estimates by $0.43. The company disclosed that cash and investments rose to $591.38 million, a figure management stated supports the current cash runway for its pipeline assets, including danicamtiv, ataciguat, and tonlamarsen. The company filed a Form 8-K with the SEC on November 12, 2026, to report these results of operations and financial condition.

Leerink lowered its price target for Kardigan to $36 from $37. The company also announced the completion of enrollment in its Phase 2b KATALYST-AV trial of ataciguat in people with aortic stenosis. Additionally, Kardigan is scheduled to participate in the Jefferies Global Healthcare Conference. A SWOT analysis based on the 10-Q filing highlighted financial strength alongside ongoing clinical challenges.

What The Data Shows

The stock opened at $13.91, representing a 1.5% gap down from the prior close of $14.12. The session high reached $14.36 at 9:30 AM ET, while the session low hit $13.07 at 9:35 AM ET. Volume so far stands at 0.0 million shares, which is 0.1 times the three-month daily average.

Kardigan has a market capitalization of $1.5 billion and remains unprofitable, with trailing twelve-month earnings per share at negative $17.13. The 52-week range for the stock is $12.23 to $27.00. Over the last eight sessions, the stock moved down 1.4%, shifting from $14.32 to $14.12. The 52-week tape recorded one fresh 52-week high and six fresh 52-week lows on November 13, 2026. The 30-day average sentiment score is 56 out of 100, while the last seven days average 52 out of 100, indicating a deteriorating trend.

What To Watch

Investors will monitor the company's upcoming participation in the Jefferies Global Healthcare Conference for further updates on its clinical pipeline and financial outlook.